Literature DB >> 28791698

Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency.

Mladen V Tzvetkov1, Johannes Matthaei1, Sherin Pojar1, Frank Faltraco, Sabrina Vogler1, Thomas Prukop1, Tina Seitz1, Jürgen Brockmöller1.   

Abstract

Fenoterol is a widely used anti-asthmatic and tocolytic agent, but high plasma concentrations of fenoterol may lead to severe and even fatal adverse reactions. We studied whether heritable deficiency of the liver organic cation transporter 1 (OCT1), a trait observed in 3% of Europeans and white Americans, affects fenoterol plasma concentrations and toxicity. OCT1 transported fenoterol with high affinity, and OCT1 inhibition in human hepatocytes reduced fenoterol uptake threefold. After administration of 180 µg of fenoterol to 39 healthy individuals, the OCT1-deficient individuals (zero active OCT1 alleles; n = 5) showed 1.9-fold greater systemic fenoterol exposure (P = 4.0 × 10-5 ) and 1.7-fold lower volume of distribution (P = 8.0 × 10-5 ). Correspondingly, the OCT1-deficient individuals had a 1.5-fold stronger increase in heart rate (P = 0.002), a 3.4-fold greater increase in blood glucose (P = 3.0 × 10-5 ), and significantly lower serum potassium levels. In conclusion, heritable OCT1 deficiency significantly increases plasma concentrations of fenoterol and may be an important factor underlying the excess mortality associated with fenoterol.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28791698     DOI: 10.1002/cpt.812

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

Review 1.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

Review 2.  Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.

Authors:  Sook Wah Yee; Deanna J Brackman; Elizabeth A Ennis; Yuichi Sugiyama; Landry K Kamdem; Rebecca Blanchard; Aleksandra Galetin; Lei Zhang; Kathleen M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2018-05-31       Impact factor: 6.875

3.  Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity.

Authors:  Bridget L Morse; John K Fallon; Anil Kolur; Andrew T Hogan; Philip C Smith; Kathleen M Hillgren
Journal:  AAPS J       Date:  2021-04-26       Impact factor: 4.009

4.  Emerging Roles of the Human Solute Carrier 22 Family.

Authors:  Sook Wah Yee; Kathleen M Giacomini
Journal:  Drug Metab Dispos       Date:  2021-12-17       Impact factor: 3.579

Review 5.  Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models.

Authors:  Bastian Haberkorn; Martin F Fromm; Jörg König
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

6.  Amino acids in transmembrane helix 1 confer major functional differences between human and mouse orthologs of the polyspecific membrane transporter OCT1.

Authors:  Marleen J Meyer; Pascale C F Schreier; Mert Basaran; Stefaniia Vlasova; Tina Seitz; Jürgen Brockmöller; Barbara Zdrazil; Mladen V Tzvetkov
Journal:  J Biol Chem       Date:  2022-04-22       Impact factor: 5.486

7.  Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.

Authors:  Marleen Julia Meyer; Tina Seitz; Jürgen Brockmöller; Mladen Vassilev Tzvetkov
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

8.  Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.

Authors:  Johannes Matthaei; Jürgen Brockmöller; Werner Steimer; Konstanze Pischa; Stefan Leucht; Maria Kullmann; Ole Jensen; Typhaine Ouethy; Mladen Vassilev Tzvetkov; Muhammad Rafehi
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

9.  Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport.

Authors:  Ole Jensen; Johannes Matthaei; Henry G Klemp; Marleen J Meyer; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

10.  OCT1 Polyspecificity-Friend or Foe?

Authors:  Marleen J Meyer; Mladen V Tzvetkov
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.